[go: up one dir, main page]

MXPA02005326A - Preparacion solida. - Google Patents

Preparacion solida.

Info

Publication number
MXPA02005326A
MXPA02005326A MXPA02005326A MXPA02005326A MXPA02005326A MX PA02005326 A MXPA02005326 A MX PA02005326A MX PA02005326 A MXPA02005326 A MX PA02005326A MX PA02005326 A MXPA02005326 A MX PA02005326A MX PA02005326 A MXPA02005326 A MX PA02005326A
Authority
MX
Mexico
Prior art keywords
compound
crystal
drug substance
granules
tablets
Prior art date
Application number
MXPA02005326A
Other languages
English (en)
Spanish (es)
Inventor
Motokazu Iwata
Original Assignee
Dainippon Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/661,577 external-priority patent/US6458824B1/en
Application filed by Dainippon Pharmaceutical Co filed Critical Dainippon Pharmaceutical Co
Publication of MXPA02005326A publication Critical patent/MXPA02005326A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MXPA02005326A 1999-11-30 2000-11-24 Preparacion solida. MXPA02005326A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP33954799 1999-11-30
US09/661,577 US6458824B1 (en) 1999-11-30 2000-09-14 Solid preparation
PCT/JP2000/008283 WO2001040182A2 (en) 1999-11-30 2000-11-24 Solid pharmaceutical preparation

Publications (1)

Publication Number Publication Date
MXPA02005326A true MXPA02005326A (es) 2003-02-12

Family

ID=26576443

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02005326A MXPA02005326A (es) 1999-11-30 2000-11-24 Preparacion solida.

Country Status (14)

Country Link
EP (1) EP1235801A2 (zh)
JP (1) JP2003515587A (zh)
CN (1) CN1433403A (zh)
AU (1) AU1550501A (zh)
CA (1) CA2391646A1 (zh)
CZ (1) CZ20021833A3 (zh)
HU (1) HUP0203865A3 (zh)
IL (1) IL149635A0 (zh)
MX (1) MXPA02005326A (zh)
NO (1) NO20022541L (zh)
NZ (1) NZ519086A (zh)
PL (1) PL356468A1 (zh)
SK (1) SK7362002A3 (zh)
WO (1) WO2001040182A2 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050010512A (ko) * 2002-06-12 2005-01-27 스미또모 세이야꾸 가부시키가이샤 인돌, 인다졸 및 벤즈아졸류
CA2509620A1 (en) * 2002-12-17 2004-07-01 Wakunaga Pharmaceutical Co., Ltd. Light-shielding agent and film-forming composition
PL1715893T3 (pl) * 2004-01-20 2010-03-31 Novartis Ag Preparat prasowany bezpośrednio oraz sposób

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3100165B2 (ja) * 1994-11-29 2000-10-16 大日本製薬株式会社 インドール誘導体
JPH11255743A (ja) * 1998-03-06 1999-09-21 Dainippon Pharmaceut Co Ltd 光学活性のインドール誘導体の製造方法及びその製造中間体

Also Published As

Publication number Publication date
HUP0203865A3 (en) 2004-05-28
NO20022541D0 (no) 2002-05-29
IL149635A0 (en) 2002-11-10
CZ20021833A3 (cs) 2003-02-12
HUP0203865A2 (hu) 2003-03-28
CA2391646A1 (en) 2001-06-07
NO20022541L (no) 2002-07-29
JP2003515587A (ja) 2003-05-07
AU1550501A (en) 2001-06-12
NZ519086A (en) 2003-11-28
CN1433403A (zh) 2003-07-30
WO2001040182A3 (en) 2002-06-27
EP1235801A2 (en) 2002-09-04
PL356468A1 (en) 2004-06-28
WO2001040182A2 (en) 2001-06-07
SK7362002A3 (en) 2003-02-04

Similar Documents

Publication Publication Date Title
TWI833686B (zh) Lsd1 抑制劑之調配物
US20210002227A1 (en) Crystalline forms of pitavastatin calcium
RU2106140C1 (ru) Фармацевтическая композиция, способ ее получения, физическая форма n-[4-[5-(циклопентилоксикарбонил)амино-1-метилиндол-3-ил-метил]-3-метоксибензоил]-2-метилбензолсульфонамида, способы ее получения
TWI306454B (en) Substituted quinoline compounds
EP1820800A1 (en) Crystalline forms of duloxetine hydrochloride and processes for their preparation
SA05260104B1 (ar) مشتقات اندول indole كمساعدات لمستقبل شبه 5-HT1
NZ288210A (en) Hydrobromide salts of 3-(n-methyl-2(r)-pyrrolidinylmethyl)-5-(2-phenylsulphonylethyl)-1h-in dole; medicaments
US6458824B1 (en) Solid preparation
CN118201927A (zh) 戊二酸利那拉赞的盐酸盐的多晶型物
EP1432681B1 (en) Pseudopolymorphic forms of carvedilol
JP2001512715A (ja) タキキニン受容体拮抗剤２−アシルアミノプロパンアミン
EA003551B1 (ru) Моногидрат гидробромида элетриптана в качестве селективного агониста 5-нтрецептора
MXPA02005326A (es) Preparacion solida.
EP2109600B1 (en) Amorphous forms of rivastigmine hydrogentartrate
AU2002338726A1 (en) Pseudopolymorphic forms of carvedilol
US20040063782A1 (en) Bicalutamide forms
EP0699665B1 (en) Imidazoline derivatives, their preparation and their use as tachykinin receptor antagonists
CN111683934B (zh) (r)-3-(1-(2,3-二氯-4-(吡嗪-2-基)苯基)-2,2,2-三氟乙基)-1-甲基-1-(1-甲基哌啶-4-基)脲的延胡索酸盐、制备方法及其用途
SK280555B6 (sk) Kryštalické monohydráty hydrochloridu endo-2,3-dih
US20040198794A1 (en) Ondansetron forms and processes of making the same
FI106021B (fi) Menetelmä N-[4-[5-(syklopentyylioksikarbonyyli)amino-1-metyyli-indol-3-yyli-metyyli]-3-metoksibentsoyyli]-2-metyylibentseenisulfonamidin fysikaalisen muodon valmistamiseksi
US20110091728A1 (en) Felbamate With Improved Bulk Density
MXPA97006872A (en) Derivatives of piperazinone substituted by heterociclico as antagonists of taquiquin receptor

Legal Events

Date Code Title Description
FA Abandonment or withdrawal